Sensorineural Hearing Loss after Combined Intensity Modulated Radiation Therapy and Cisplatin-Based Chemotherapy for Nasopharyngeal Carcinoma
| Autor: | Shao Ming Huang, Yuan Yuan Chen, X. Allen Li, Xue Lin Chen, Cungen Yang, Yong Bao, An Tai, Ming Chen, Chong Zhao, Xiao Wu Deng, Jin Wang, Ning Wei Li |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Cisplatin
Original article Cancer Research medicine.medical_specialty Univariate analysis Pathology Chemotherapy medicine.diagnostic_test business.industry medicine.medical_treatment Incidence (epidemiology) lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease lcsh:RC254-282 Gastroenterology Radiation therapy Oncology Nasopharyngeal carcinoma Internal medicine otorhinolaryngologic diseases medicine Sensorineural hearing loss Pure tone audiometry business medicine.drug |
| Zdroj: | Translational Oncology Translational Oncology, Vol 8, Iss 6, Pp 456-462 (2015) |
| ISSN: | 1936-5233 |
| DOI: | 10.1016/j.tranon.2015.10.003 |
| Popis: | PURPOSE: The incidence of sensorineural hearing loss (SNHL) after treatment with combination of intensity-modulated radiation therapy (IMRT) and cisplatin-based chemotherapy in nasopharyngeal carcinoma (NPC) patients was evaluated, and relationships of SNHL with host factors, treatment-related factors, and radiation dosimetric parameters were investigated. METHODS: Fifty-one NPC patients treated with IMRT from 2004 to 2009 were analyzed. All patients received neoadjuvant, concurrent, or adjuvant use of cisplatin. Pure tone audiometry was performed during the follow-up period with a median time of 60 months, ranging from 28 to 84 months. Correlation of SNHL at low frequencies (pure tone average, 0.5-2 kHz) with a series of factors was analyzed. RESULTS: Among 102 ears, 12.7% had low-frequency SNHL and 42.2% had high-frequency (4 kHz) SNHL. The incidence of low-frequency SNHL was greater in patients with age > 40, with T-stage 4, or who received cumulative cisplatin dose (CCD) > 200 mg/m2 (P = .034, .011, and .003, respectively) and in ears with secretory otitis media (SOM) (P = .002). Several dosimetric parameters were found to be correlated with SNHL. Univariate analysis showed that the minimum radiation dose to 0.1 ml highest dose volume (D0.1 ml) of the cochlea was the best radiation-related predictive parameter. Multivariate analysis indicated that CCD, SOM, and D0.1 ml of cochlea (P = .035, .012, and .022, respectively) were the factors associated with SNHL. CONCLUSION: For NPC patients treated with IMRT and chemotherapy, the incidence of treatment-related SNHL was associated with CCD, D0.1 ml of cochlea, and SOM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|